D-gest10 mg

D-gest is a synthetic, orally active progestogen (a "retroprogesterone") used in a range of gynecological and obstetric conditions related to progesterone deficiency. Its indications can be grouped by strength of evidence and regulatory/guideline support as follows:

Established / widely approved uses

• Dysfunctional uterine bleeding — to control acute episodes and to prevent recurrence.
• Secondary amenorrhea — typically given together with an estrogen.
• Irregular menstrual cycles due to progesterone deficiency.
• Endometriosis — to suppress ectopic endometrial tissue activity.
• Premenstrual syndrome (PMS) and dysmenorrhea associated with luteal insufficiency.
• Progestogen component of hormone replacement therapy (HRT) — combined with estrogen to protect the endometrium from unopposed estrogen stimulation in non-hysterectomised women.

Guideline-supported obstetric uses (regional variation in evidence and endorsement)

• Threatened miscarriage — used under medical supervision in women with a viable pregnancy and clinical signs of threatened miscarriage; several national obstetric guidelines and regulatory labels in Asia, Europe and elsewhere support this use, although evidence quality is debated and practice varies by country.
• Recurrent (habitual) miscarriage — used in women with a history of three or more consecutive miscarriages, generally started before conception or in early pregnancy and continued under specialist supervision.

Adjunct / fertility-related use

• Luteal phase support / infertility due to luteal insufficiency — as an adjunct in the management of infertility associated with inadequate luteal progesterone production, sometimes as part of assisted reproduction protocols.

Note: D-gest is not approved by the US FDA and is not marketed in the United States; the uses above reflect labeling and guideline support in countries (including Bangladesh) where it is registered and prescribed. Any use should be individualized and supervised by a qualified physician.

Each film-coated tablet contains Dydrogesterone INN 10 mg as the active ingredient, along with pharmaceutically approved excipients. Dydrogesterone is also available in some markets as part of fixed-dose combination tablets with estradiol for hormone replacement therapy; such combination products carry separate composition and dosing information.

D-gest is a synthetic steroidal progestogen structurally very close to natural progesterone, differing by a reversal ("retro") of one ring configuration and an added double bond. This retro-configuration gives it high oral bioavailability and a progestogenic profile that closely mimics endogenous progesterone, while largely avoiding the estrogenic, androgenic, anabolic, corticoid and thermogenic (body-temperature-raising) effects seen with some other synthetic progestins.

D-gest is used clinically wherever a relative or absolute deficiency of natural progesterone contributes to a gynecological or early-pregnancy disorder, including threatened and recurrent miscarriage, dysfunctional uterine bleeding, secondary amenorrhea, endometriosis, premenstrual syndrome and as the progestogen component of hormone replacement therapy.

Progestogens — D-gest is classified as a retroprogesterone, a synthetic progestogen used in gynecology and obstetrics.

Dydrogesterone binds selectively and with high affinity to the progesterone receptor, producing a full progestational effect on estrogen-primed endometrium and myometrium, similar to endogenous progesterone. Unlike many synthetic progestins, it has little or no estrogenic, androgenic, anabolic, corticoid or thermogenic activity at recommended doses, and at these doses it does not consistently inhibit ovulation, which is why it can be used for luteal support without necessarily suppressing the woman's own cycle.

After oral administration, Dydrogesterone is rapidly and almost completely absorbed, undergoes extensive first-pass hepatic metabolism to its main active metabolite (20α-dihydrodydrogesterone, DHD), and is eliminated mainly via the kidneys with a plasma half-life of a few hours. Its high, predictable oral bioavailability is the main pharmacokinetic advantage over natural micronized progesterone.

D-gest tablets are for oral use only. Swallow the tablet whole with a glass of water. It may be taken with or without food. For indications dosed twice daily, doses should be spaced approximately 12 hours apart (or every 8 hours for the acute threatened-miscarriage regimen) and taken at consistent times each day to maintain steady hormone levels.

If a dose is missed, it should be taken as soon as remembered unless it is almost time for the next dose, in which case the missed dose should be skipped — do not double the dose. Do not stop treatment abruptly, particularly during pregnancy-related use, without consulting the prescribing physician.

D-gest is metabolized in the liver, mainly via CYP3A4-mediated pathways, so drugs that induce or inhibit this enzyme can alter its blood levels and effect:

• CYP3A4 inducers (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital, and herbal products such as St. John's Wort) may lower plasma concentrations of D-gest, potentially reducing its efficacy; closer clinical monitoring or dose adjustment may be needed.
• CYP3A4 inhibitors (e.g., certain azole antifungals, macrolide antibiotics, protease inhibitors) may theoretically increase D-gest levels, raising the chance of progestogen-related side effects.
• Other hormonal medications (estrogens, other progestogens/progestins, hormonal contraceptives) can have additive or interacting effects on the endometrium and menstrual cycle; combinations should be supervised by a physician.

Patients should inform their physician of all prescription, over-the-counter and herbal products they are taking before starting D-gest.

D-gest is generally well tolerated. Reported adverse effects include:

• Common: breast tenderness or pain, headache or migraine, nausea, breakthrough bleeding or spotting, and mood changes (including low mood or irritability).
• Less common: dizziness, abdominal discomfort, fluid retention, and menstrual irregularities.
• Rare: hypersensitivity reactions (rash, itching, swelling) and liver function abnormalities.

Patients should report persistent or severe side effects, unexpected vaginal bleeding, or signs of an allergic reaction to their physician promptly.

Pregnancy: D-gest has a specific, labeled use during pregnancy — for threatened miscarriage and for prevention of recurrent miscarriage — and is used for these indications under direct medical supervision, with the physician judging that the expected benefit outweighs any potential risk. Outside of these specific obstetric indications, D-gest should be used in pregnancy only if clearly needed and only on a physician's advice.

Lactation: It is not established whether D-gest or its metabolites pass into breast milk in clinically significant amounts. As a precaution, use during breastfeeding should occur only if considered necessary by the treating physician, who will weigh the benefit to the mother against any potential effect on the breastfed infant.

Before starting D-gest, patients should be evaluated for conditions that warrant closer monitoring:

• Unexplained vaginal bleeding occurring during treatment should be investigated to exclude organic pathology, as it can otherwise be masked (see also Contraindications for bleeding that is undiagnosed before treatment).
• History of depression — patients should be monitored, as progestogens can occasionally affect mood; treatment should be stopped if depression becomes severe.
• Hepatic impairment — since D-gest is extensively metabolized by the liver, it should be used with caution and closer monitoring in patients with significant hepatic disease (see Use in Special Populations).
• History of thromboembolic disease — relevant particularly when D-gest is used as part of combined hormone replacement therapy with an estrogen; such combinations carry a background risk of venous thromboembolism related mainly to the estrogen component, and individual risk factors should be assessed.
• Fluid-retaining conditions (e.g., epilepsy, migraine, cardiac or renal dysfunction) — monitor patients carefully as with other progestogens.

D-gest does not act as a contraceptive; women who wish to avoid pregnancy should use an additional, reliable method unless D-gest is specifically being used to support a desired pregnancy.

Reported experience with acute overdose of D-gest is limited, and it is generally considered to have a wide margin of safety. Symptoms that might be expected with significant overdose include nausea, vomiting, drowsiness, and irregular vaginal bleeding.

There is no specific antidote. If an overdose is suspected, seek immediate medical attention or contact a poison control center; treatment is supportive and symptomatic, guided by a physician. Do not attempt specific home treatment for an overdose.

Store at room temperature (below 30°C), protected from light and moisture. Keep out of reach of children.

Hepatic impairment: D-gest is extensively metabolized by the liver; it should be used with caution in patients with hepatic impairment, and is not recommended in patients with severe liver disease or a history of certain rare hereditary hepatic conditions affecting bilirubin excretion, unless specifically advised by a physician.

Renal impairment: No formal dose adjustment has been established; limited data exist, so use with caution and physician supervision in significant renal impairment.

Elderly: D-gest is not indicated for use in postmenopausal women except as the progestogen component of hormone replacement therapy alongside an estrogen; it has no role in elderly men.

Children: Not indicated for use in premenarchal children; safety and efficacy have not been established in this population (see also Pediatric Uses).

Duration of treatment with D-gest varies widely by indication: a single acute episode of dysfunctional uterine bleeding may be treated for as little as 5–7 days, cyclical gynecological indications (endometriosis, secondary amenorrhea, PMS, luteal-phase support) are typically continued for several menstrual cycles with periodic physician review, and pregnancy-related indications (threatened or recurrent miscarriage) may be continued for one week after symptoms resolve up to as long as the 20th week of pregnancy under specialist supervision. When used in hormone replacement therapy, treatment continues for as long as HRT remains clinically indicated. The physician will determine the appropriate duration and reassess periodically.

Sex hormones and modulators of the genital system > Progestogens > Retroprogesterone derivatives

Dydrogesterone acts as a selective agonist at the progesterone receptor, reproducing the secretory transformation and other physiological effects that natural progesterone exerts on estrogen-primed endometrium, without significant activity at estrogen, androgen, mineralocorticoid or glucocorticoid receptors. This selectivity allows it to provide progestogenic support (for example, protecting the endometrium during estrogen therapy, or supporting the luteal phase and early pregnancy) while minimizing the androgenic and metabolic side effects associated with some other synthetic progestins.

D-gest is not indicated for use in premenarchal children, and safety and efficacy in this population have not been established. It is used in adolescent and adult women of reproductive age for the approved gynecological and obstetric indications, with dosing as for adults once menstrual cycles are established; treatment in adolescents should be initiated and supervised by a specialist physician.